Apex Biotechnology

Apex Biotechnology Gross Margin

The Gross Margin of Apex Biotechnology (1733.TW) as of Nov 22, 2026 is 27.70 %. In the previous year, Gross Margin was 28.15 % — a change of -1.59% (lower).

Gross Margin

27.70 %

YoY

-1.59%

Last updated:

Gross Margin of Apex Biotechnology is 2025 27.70 % . Gross Margin of Apex Biotechnology was 2024 28.15 % . It decreases by -1.59% lower compared to the previous year.

For Apex Biotechnology, the gross margin of 27.7% is broadly stable versus 26.8% a few years ago.

The Apex Biotechnology Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
27.41 TWD
Jan 1, 2019
26.86 TWD
Jan 1, 2020
22.55 TWD
Jan 1, 2021
26.81 TWD
Jan 1, 2022
25.70 TWD
Jan 1, 2023
31.68 TWD
Jan 1, 2024
28.15 TWD
Jan 1, 2025
27.70 TWD
The Apex Biotechnology Gross Margin history
YEARGross MarginYoY
27.70 %-1.59%
28.15 %-11.15%
31.68 %+23.25%
25.70 %-4.13%
26.81 %+18.89%
22.55 %-16.04%
26.86 %-2.00%
27.41 %+14.03%
24.04 %-11.12%
27.04 %-8.69%
29.62 %+0.98%
29.33 %+9,337.89%
0.31 %-22.11%
0.40 %-0.08%
0.40 %-7.32%
0.43 %+1.23%
0.43 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Apex Biotechnology Stock analysis

What does Apex Biotechnology do? Apex Biotechnology Corp is a Taiwan-based company specializing in the development of innovative biotechnology products. The company was founded in 2002 and offers a wide range of products and services to its customers. Apex Biotechnology Corp began with the production of specialty chemicals and enzymes for research and development purposes. Over the years, the company has expanded its business and focused on the development of diagnostic products, dietary supplements, and pharmaceutical products. The company's business model focuses on the development and marketing of biotechnology products. Apex Biotechnology Corp has established advanced research centers and works closely with research institutions and pharmaceutical companies worldwide to develop innovative solutions. The company operates in various sectors, including diagnostics, dietary supplements, and pharmaceuticals. It offers a diverse range of products, including enzyme immunoassays, lateral flow tests, dietary supplements, and pharmaceuticals. Apex Biotechnology Corp has built strong relationships with research institutions and pharmaceutical companies and has successfully marketed its products internationally. Apex Biotechnology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Apex Biotechnology stock

Gross Margin of Apex Biotechnology is 27.70 % in 2025.

Gross Margin of Apex Biotechnology changed from 28.15 % to 27.70 %, representing a -1.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Apex Biotechnology since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Apex Biotechnology with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Apex Biotechnology

All Key Metrics — Apex Biotechnology